NCT02115854

Labial Biopsy in Patients With Tuberculosis Disease

Name: Clinical Trial NCT02115854
Creator: Hopital Lariboisière
Keywords: Tuberculosis,Sarcoidosis, labial biopsy, other, clinical trial, France

The Value of Labial Biopsy in 65 Patients With Tuberculosis Disease

Hopital Lariboisière·ClinicalTrials.gov·otherCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Tuberculosis,Sarcoidosis
Drug/Device/Intervention: labial biopsy
Study type: Observational
Intervention type: other

Sponsor & location

Primary sponsor: Hopital Lariboisière
Location: Paris, France

Timeline & enrollment

Phase: N/A
Start date: Dec 01, 2010
End date: N/A
Enrollment: 65 participants

Primary outcome

presence of granuloma on labial biopsy

Summary

The distinction between Tuberculosis disease (TB), a worldwide infective granulomatosis requiring long-term antibiotic treatment, and sarcoïdosis, a rare granulomatous disease successfully treated with high dose steroids is not straightforward and may delay the treatment choice by the physician.  The goal was to evaluate prospectively and consecutively the presence of epithelioid granulomas in salivary glands biopsy of patients with TB.

ICD-10 classifications

SarcoidosisSarcoidosis, unspecifiedSarcoidosis of lungSarcoidosis of lymph nodesSarcoidosis of other and combined sites

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT02115854
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT02115854 through Pure Global AI's free database. This phase not specified trial is sponsored by Hopital Lariboisière and is currently Completed. The study focuses on Tuberculosis,Sarcoidosis. Target enrollment is 65 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.